Changes in Hong Kong stocks | Cornerstone Pharmaceutical-B (02616) rose more than 8% in the afternoon, the two drugs plan to start preparations for clinical trial applications for new drugs in the second half of the year

Zhitongcaijing · 07/04 06:41

The Zhitong Finance App learned that Cornerstone Pharmaceutical-B (02616) rose more than 8% in the afternoon. As of press release, it had risen 8.28% to HK$4.97, with a turnover of HK$57,1882 million.

According to the news, Cornerstone Pharmaceuticals announced that, for the first time, two independently developed bispecific antibody drug targets for autoimmune/inflammatory diseases, including CS2013 (B Cell Activating Factor [BAFF]/Proliferation-Inducing Ligand [APRIL]) and CS2015 (OX40 Ligand [OX40L]/Thymic Matrix Lymphopoietin [TSLP]).

According to the announcement, the two drugs have best-in-class/first-in-class potential. Currently, they are both in the preclinical candidate compound (PCC) confirmation stage, and pre-clinical research data will be presented at relevant international academic conferences. In addition, Cornerstone Pharmaceuticals plans to begin preparation of the New Drug Clinical Trial Application (IND) in the second half of 2025.